Another serious alarm is being raised over the way the National Agency for Medicines and Medical Devices, under the direct influence of Klodian Allajbeu and Rasim Hamzaraj, is exercising its responsibility towards public health.
At the center of concern is an antitumor drug manufactured in Malta with a local representative, the pharmaceutical distributor Megapharma, which, according to reliable sources, did not meet laboratory criteria during initial analysis, but has nevertheless advanced in the registration process.
According to the same sources, the first samples submitted for analysis proved problematic, and were later replaced with other samples, which enabled the procedure to continue. Such a practice constitutes a serious violation of pharmaceutical safety principles and a direct risk to oncology patients.
The questions that arise are why new samples were accepted after the initial tests failed and who made this decision. The concern is whether the drug agency is functioning as a guarantor of safety, or as a formal link that turns a blind eye.
The Medicines Agency has a legal and moral obligation to publicly clarify whether the procedures followed, the real results of laboratory tests, and the reasons why a contested product passed official filters. Patients' health is not a statistic and cannot be treated as an administrative formality.
Top Channel has requested information from the National Medicines Agency on this case, asking how many applications for marketing authorization were received during 2025 for the drug Nilotinib and the relevant dates? Who are the operators? Were these drugs analyzed during the marketing authorization procedure? What were the results of the analysis? If the drug showed problems during the analysis, what measures were taken against the operators who applied? Were these practices rejected? If not all practices were rejected, what are the reasons for this differentiated treatment of the applications and consequently of the operators? Has there been any further progress in providing marketing authorization for these drugs? If so, who are the operators that have received marketing authorization?
This scandal is sufficient material for SPAK to investigate and clarify what is happening to protect the interests of patients, while currently it seems that they have been left in the hands of hunger for the financial benefits of Klodian Allajbeu, Rasim Hamzaraj and Petrit Vasili. /Top Channel/
